Seeking mTORC1 Inhibitors Through Molecular Dynamics Simulation of Arginine Analogs Inhibiting CASTOR1

LIANG SUN1,2*, XINYU LI3*, JUN PAN1, JIASHUN MAO1, YUEYANG YUAN1,4, DUOXI WANG1, WEIWEI SUN5, GERHARD R.F. KRUEGER6 and GUANYU WANG1,2,4,7

1Department of Biology, Southern University of Science and Technology, Shenzhen, P.R. China; 2Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research, Shenzhen, P.R. China; 3School of Life and Health Sciences and Warshel Institute for Computational Biology, The Chinese University of Hong Kong, Shenzhen, P.R. China; 4Guangdong Provincial Key Laboratory of Computational Science and Material Design, Shenzhen, P.R. China; 5Department of Pathology, Shanghai Songjiang Central Hospital, Shanghai, P.R. China; 6Department of Pathology and Laboratory Medicine, University of Texas-Houston Medical School, Houston, TX, U.S.A.; 7Shenzhen Key Laboratory of Cell Microenvironment, Shenzhen, P.R. China

Abstract. Background: Hyperactivity of the mechanistic target of rapamycin complex 1 (mTORC1) is implicated in a variety of diseases such as cancer and diabetes. Treatment may benefit from effective mTORC1 inhibition, which can be achieved by preventing arginine from disrupting the cytosolic arginine sensor for mTORC1 subunit 1 (CASTOR1)–GTPase-activating proteins toward RAGS subcomplex 2 (GATOR2) complex through binding with CASTOR1. An attractive idea is to determine analogues of arginine that are as competent as arginine in binding with CASTOR1, but without disrupting the CASTOR1–GATOR2 interaction. Materials and Methods: Molecular dynamics simulations were performed for binding of arginine analogues with CASTOR1 and binding free energy, hydrogen bond formation, and root mean squared deviation and root mean square fluctuation kinetics were then calculated. Results: The binding free energy calculations revealed that Nα-acetyl-arginine, citrulline, and norarginine have sufficient binding affinity with CASTOR1 to compete with arginine. The hydrogen bond analysis revealed that norarginine, Nα-acetyl-arginine and D-arginine have proficient H-bonds that can facilitate their entering the narrow binding pocket. Conclusion: Norarginine and Nα-acetyl-arginine are the top drug candidates for mTORC1 inhibition, with Nα-acetyl-arginine being the best choice.

Mechanistic target of rapamycin (mTOR) in complex with regulatory-associated protein of mTOR (RAPTOR) and mTOR-associated protein, LST8 homolog (LST8) is referred as mTOR complex 1 (mTORC1). It is implicated in diseases in which growth is deregulated and homeostasis is compromised (1). Deregulated mTORC1 signalling fuels the destructive growth of cancer. Overstimulation of the mTORC1 pathway by excess food consumption may be a crucial factor underlying the diabetes epidemic (2-4). Recent findings suggest that mTORC1 signalling controls the rate at which cells and tissues age, and that inhibiting mTORC1 may represent a promising avenue for increasing longevity (5). In particular, dysregulation of signalling pathways upstream of mTORC1 can cause human diseases such as cancer, metabolic diseases, neurological disorders, and autoimmune diseases (6, 7).

In order for cells to grow and proliferate by manufacturing more proteins, the cells must ensure that they have the resources (energy, nutrients, oxygen, and growth factors) available in order for mRNA translation to begin (5, 8, 9).
Nutrient availability is primarily sensed as the intracellular amino acid level, by the RAGULATOR–RAG complex sitting on the surface of the lysosome (10). Figure 1 uses leucine and arginine as examples to illustrate the pathway by which amino acids activate mTORC1. The RAGULATOR–RAG complex is formed by RAGULATOR and RAG GTPases, with the former serving as the scaffold of the latter. The RAG-GTPases form heterodimeric complexes comprised of RAGA or RAGB bound to RAGC or RAGD (11). To form the RAGULATOR–RAG complex, RAGA/B must be GTP loaded (12, 13) and RAGC/D must be GDP loaded (14, 15). This complex causes mTORC1 to be translocated from the cytoplasm to the lysosomal surface, which allows for the activation of mTORC1 by the lysosome-anchored small GTPase Ras homolog enriched in brain (RHEB) (13, 16).

GTPase-activating proteins toward RAGS subcomplex 1 (GATOR1) prevents RAGA/B from loading GTP and thus prevents the formation of the RAGULATOR–RAG complex and subsequent mTORC1 activation (17). To activate mTORC1, GATOR1 must be inhibited, and its upstream inhibitor is GATOR2. However, GATOR2 is usually associated with other proteins and is thus inactivated. These GATOR2-associating proteins are sensors for amino acids and there are a variety of them. For example, SESTRIN2 is a cytosolic leucine sensor (11) and CASTOR1 is an arginine sensor (6). These amino acids, when binding with their corresponding sensor proteins, can disrupt the association of the sensor proteins with GATOR2 (Figure 1). Released GATOR2 inhibits GATOR1 and ultimately leads to activation of mTORC1. For example, the amino acid leucine disrupts the GATOR2–SESTRIN2 complex and ultimately activates mTORC1 (11).

The present study focused on arginine, whose sensor is the protein CASTOR1. In order to associate with GATOR2, CASTOR1 needs to either homodimerize or heterodimerize with CASTOR2 (6), in a complex denoted by CASTOR1–GATOR2, which refers to either CASTOR1–CASTOR1–GATOR2 or CASTOR1–CASTOR2–GATOR2. Arginine, when present at sufficient concentrations, can bind to the conserved ACT domains of CASTOR1 and subsequently disrupts the CASTOR1–GATOR2 complex (18, 19). As a consequence, GATOR2 dissociates from CASTOR1–homodimer or CASTOR1–CASTOR2, leading to the ultimate activation of mTORC1 (6, 11).

Given that mTORC1 hyperactivation underlies complex diseases such as cancer and diabetes, this study considered methods of mTOR inhibition. From the above, it is clear that maintenance of CASTOR1–GATOR2 association is key to inhibition of mTORC1. That is, as long as GATOR2 is associated with either CASTOR1–CASTOR1 or CASTOR1–CASTOR2, it has no opportunity to activate the downstream mTORC1. Therefore, the key to preventing mTORC1 hyperactivation is to maintain integrity of the CASTOR1–GATOR2 association. This association is, however, difficult to maintain, because arginine is ubiquitously present in cells, which can easily bind with CASTOR1 and subsequently disrupt the CASTOR1–GATOR2 association. It is thus highly desirable to develop small-molecule drugs that can occupy the binding pocket of CASTOR1 to arginine and still maintain integrity of the CASTOR1–GATOR2 interaction. Naturally, arginine analogues are potential drug candidates for fulfilling the above requirements, namely, to target the conserved ACT domain of CASTOR1 for the treatment of diseases related to mTORC1 hyperactivation.

The arginine analogues reported by Saxton et al. (18) drew our attention. These arginine analogues can be divided into two groups (Figure 2): those that can disrupt the CASTOR1–GATOR2 interaction (called the disruption group) and those that cannot (called the non-disruption group). The disruption group includes L-arginine, canavanine (a non-proteinogenic amino acid with the sole difference from arginine being the replacement of a methylene bridge in arginine with an oxygen atom in canavanine), and a carboxy-modified arginine-methyl ester (arginine-OMe). The non-disruption group includes compounds with alterations to the guanidinium group, α-amine, or the length of the side chain (18). In this study, the interactions between these arginine analogues and CASTOR1 were studied at the atomic level by molecular dynamics simulation (MD simulation) in order to provide insights into development of drug candidates targeting mTORC1 hyperactivation. Specifically, we aimed to select inhibitors from the non-disruption group that are sufficiently competitive with arginine in terms of binding with CASTOR1.

Materials and Methods

Structure preparation. CASTOR1 protein, arginine and arginine analogues, water and ions were used to construct the simulation system. The atomic coordinates of CASTOR1 were obtained from the crystal structure 5I2C, which was an arginine bound human CASTOR1 structure (20). To obtain the pure CASTOR1 structure, arginine and water molecules were removed and the missing amino acids were then complemented by homology modelling. The protein was then minimized and equilibrated in a water box with salt for 1000 ns by MD simulation. The 10 arginine analogues (Figure 2) were then prepared in silico. They were drawn by Discovery Studio 2016 client software (BIOVIA, San Diego, CA, USA). They were then respectively docked to the CASTOR1 structure to start MD simulation.

Simulation methods. MD simulation is a powerful method for studying the kinetics of protein–ligand binding (21, 22). Molecular docking, MD simulation, and free energy calculation methods were used in this work. Molecular docking of each small-molecule drug to the active site of CASTOR1 was performed by AutoDock Vina (The Scripps Research Institute, San Diego, CA, USA) (23). Docking simulations not only provide the binding affinity data but...
also obtain the optimized holo-system for the subsequent MD simulation. Ten simulation boxes were then built to simulate the MD of the 10 small molecules interacting with CASTOR1. Before the MD simulation, TIP3P water model (24) was employed to build the water box and some chlorine or sodium ions were added to neutralize the system. AMBER16 package (25) was employed to run all the MD simulations with leaprc.protein.ff14SB (26) as the force field for the protein, and General Amber Force field (GAFF) (27) as the force field for the arginine analogues.

Simulation protocol. For each simulation box, energy minimization was first performed to obtain a low-energy starting conformation for the subsequent MD simulations. Four-thousand steps of steepest descent method was first employed followed by six-thousand steps of conjugate gradient method. The whole system (protein, ligand, water, ions) was first minimized, followed by minimization on the solutes (protein and ligand) only. With the Langevin thermostat applied, the system was heated under canonical ensemble from 0 to 303 K for 300 ps, with the force constant for the harmonic restraint set at 10.0 kcal mol$^{-1}$ Å$^{-2}$. The system was then equilibrated for 10 ns under isothermal-isobaric conditions (with constant pressure of 1.0 bar). The relaxation time for the barostat bath was set at 2.0 ps. Finally, the production simulation was run for 100 ns under isothermal-isobaric conditions with periodic boundary conditions. The time step was set at 2 fs and bonds connected with hydrogen atoms were constrained using the SHAKE algorithm. The long-range electrostatics was handled by the particle-mesh Ewald method (28). The cut-off value for short range interactions was set at 10.0 Å. The production simulation was repeated three times in order to calculate the average.

Binding free energy calculation. The free energy of CASTOR1 binding to arginine analogue was calculated by the molecular mechanics energies combined with the generalized born and surface area continuum solvation method (29-32). In order to identify the most crucial residues of CASTOR1 for the binding of the arginine analogue, the total binding free energy was decomposed into contributions from individual residues (i=1, 2, ..., 342):

$$
\Delta G_{\text{bind}} = \sum_{i=1}^{342} \Delta G_{\text{bind}}^i = \sum_{i=1}^{342} \sum_{j=1}^{342} \Delta G_{\text{bind}}^{ij}
$$

where $\Delta G_{\text{bind}}^i$ were the per-residue contributions, and $\Delta G_{\text{bind}}^{ij}$ were the residue-pairwise interaction contributions. The calculations were rendered by the MMPBSA.py.MPI module (33) of AMBER16.

Results

Root mean square deviation (RMSD) and root mean square fluctuation (RMSF). MD simulations were performed on the 10 arginine analogue systems to reveal the overall dynamical
features of the binding between CASTOR1 and arginine analogues, and to determine the difference between the disruption and the non-disruption groups. The calculation of RMSD can be used to investigate the variation and stability of protein–drug complex. The disruption group consisted of three arginine analogues (arginine, canavanine, and arginine-OMe) and their RMSD results are presented in Figure 3A. It can be seen that the initial unsteady state lasted about 20 ns before the atoms stably oscillated around their new positions. For the L-arginine system, the new position was about 3.75 Å away from the initial position during 20 to 80 ns, after which the atoms moved a little further away (4 Å). For the canavanine and arginine-OMe systems, the new position was about 2.75 Å away from the initial position during 20 to 80 ns, after which the atoms also moved a little further away (3 Å). The non-disruption group consisted of seven arginine analogues and their RMSD results are presented in Figure 3B. Except D-arginine, the atoms behaved similarly to those of the disruption group, oscillating around a new position some 3 Å away from the initial position. The D-arginine system atoms fluctuated considerably between 30 ns and 70 ns before finally stabilizing 3.75 Å away from the initial position. This difference appeared to be attributed to the chiral carbon distinguishing D-arginine from arginine. These results demonstrate that arginine and D-arginine exerted much stronger influence on protein conformation than the other arginine analogues.

RMSF analysis was then used to estimate the fluctuations of each amino acid residue over the simulation time. We
Figure 3. Time course of root mean square deviation (RMSD) values for the disruption (A) and non-disruption (B) groups of arginine analogues.
found that most of the systems fluctuated considerably around amino acids 25-50, 75-100, 150-175, 250-275 and 300-325 (Figure 4). Note that these residues belong to the domains ACT2 and ACT4, which concurs with the fact that CASTOR1 bound to arginine through a narrow pocket at the interface of ACT2 (amino acids 75-156) and ACT4 (amino acids 259-329) (1). Therefore, the differences of the arginine analogues from arginine do not alter their approximate docking site on CASTOR1. However, there was one significant difference between arginine and its analogues. In the arginine system, residue Lys213 of CASTOR1 had the highest RMSF value, indicating its large fluctuation. Surprisingly, Lys213 does not locate on the interface of ACT2 and ACT4.

![Graph showing time course of root mean square fluctuation (RMSF) values for the disruption (A) and non-disruption (B) groups of arginine analogues.](image)

**Figure 4.** Time course of root mean square fluctuation (RMSF) values for the disruption (A) and non-disruption (B) groups of arginine analogues.

| Analogue               | ∆G_{bind} (kcal mol^{-1}) |
|-----------------------|---------------------------|
| **Disruption group**  |                           |
| Arginine              | −44.6420                  |
| Canavanine            | −33.3440                  |
| Arginine-OMe          | −39.7628                  |
| **Non-disruption group** |                         |
| Citrulline            | −31.5504                  |
| Norarginine           | −29.7002                  |
| Ornithine             | −17.0416                  |
| Homoarginine          | −16.0391                  |
| Nα-Acetyl-arginine    | −36.2542                  |
| Lysine                | −20.1681                  |
| D-Arginine            | −17.0416                  |

**Table I. Summary of binding free energy for arginine analogues with cytosolic arginine sensor for mechanistic target of rapamycin complex 1 subunit 1.**
Binding free energy analysis. Affinity of enzyme–substrate binding can be estimated by calculating the free energy of binding $\Delta G_{\text{bind}}$. In this study, the last 20 ns of the MD simulation was used to calculate the binding free energy by using the MM-GBSA method. With the lowest binding free energy $\Delta G_{\text{bind}}$ of $-44.6420$ kcal mol$^{-1}$, the arginine system was the most stable complex among the 10 systems (Table I). Moreover, the binding of molecules of the disruption group with CASTOR1 was generally more stable than that of the non-disruption group, which demonstrates that our choice of drug candidates would not be abundant. Nevertheless, $N_{\alpha}$-acetyl-arginine in the non-disruption group had $\Delta G_{\text{bind}}$ of $-36.2542$ kcal mol$^{-1}$, which was the third lowest binding free energy and was even lower than that of canavanine in the disruption group. Therefore, $N_{\alpha}$-acetyl-arginine might be a strong candidate if other measures (such as hydrogen bonding; see below) are also suitable. Besides $N_{\alpha}$-acetyl-arginine, citrulline and norarginine in the non-disruption group also had very low binding free energy with CASTOR1 (around $-30$ kcal mol$^{-1}$). Therefore, $N_{\alpha}$-acetyl-arginine, citrulline, and norarginine may be competitors of arginine and are thus potential drug candidates.

Hydrogen bond (H-bond) analysis. H-Bond analysis is important in structure-based drug design. In general, the more H-bonds formed, the more stable the interaction. If an
inhibitor in the non-disruption group forms significantly more H-bonds with CASTOR1 than arginine does, then it would be a good candidate mTORC1 inhibitor. We therefore performed a comprehensive H-bond analysis of the 10 systems. During the 100 ns MD simulation of each system, the real-time formation of H-bonds was monitored, and the results are presented in Figure 5. To comprehend more intuitively, the structure of the binding pocket formed by the ligand and its surrounding amino acid residues is illustrated, with the primary H-bonds indicated by green dashed lines (Figure 6).

We first analysed the disruption group. For arginine, its C-terminus and N-terminus mainly form H-bonds with nearby CASTOR1 residues such as Ile280, Gly279, Cys278, Val112, and Ser111. At the other end, the guanidine group interacts with Gly274, Asp304, Thr300, and Phe301. The molecule arginine-OMe is derived from arginine by replacement of the carboxyl group with an ester group, which causes a small rotation abolishing the H-bond between the C-terminus and Cys278 and generating a new H-bond between the C-terminus and Val281. The rotation also abolishes the H-bond between the N-terminus and Phe301 and generates a new H-
bond between the N-terminus and Ser299. Canavanine is derived from arginine by replacing C-5 with an oxygen atom, which reduces H-bond availability on Ser111 and Cys278. It is clear that arginine-OMe and canavanine do not differ significantly from arginine as far as H-bonding is concerned. The results demonstrate consistency of the MD simulation and H-bond analysis for the three molecules.

In the non-disruption group, we first analysed lysine, ornithine, and citrulline, which are derived from arginine by replacing the guanidine group with three other groups. This replacement does not enhance H-bonding because the lost guanidine group is an important H-bond donor. Given that the replacements are more thorough in lysine and ornithine (from the guanidine group to N2H), the two analogues would have greater loss of H-bonds. Indeed, lysine and ornithine fail to form important H-bonds with Phe301 and Asp304 due to the lack of two H-bond-donating nitrogen atoms in the guanidinium group. For citrulline, the guanidine group is replaced by a bio-isostere, and the substitution of oxygen for imidogen provides a new H-bond interaction between the O
atom and Phe275, at the expense of losing a H-bond with key residue Ser111 of CASTOR1. Therefore, among the three molecules, citrulline is much more appropriate as a drug candidate than the other two because it creates more H-bonds and its ΔG_{bind} is low (−31.5504 kcal mol⁻¹). However, citrulline would not be a strong competitor of arginine because the total number of H-bonds appears to be lower.

We then analysed the remaining four arginine analogues in the non-disruption group. Homoarginine and norarginine are structurally related to arginine by elongating and shortening the side chain of arginine by just one carbon unit, respectively. The norarginine system might be more stable than the homoarginine system because norarginine forms many more H-bonds with CASTOR1 than does homoarginine (Figure 5). We therefore analysed the H-bonds of norarginine in more detail and found that they are similar to those of canavanine. Moreover, the number of H-bonds appeared to be greater than in the arginine system. For Nα-acetyl-arginine, the formamide group provides an H-bond interaction with Val281. For D-arginine, the chiral change makes NH2 interact with Gly277. More importantly, we
found that both $N_\alpha$-acetyl-arginine and D-arginine form more H-bonds than does the arginine system.

The H-bond analysis revealed that norarginine, $N_\alpha$-acetyl-arginine and D-arginine are competitive with arginine in binding with CASTOR1. Unlike arginine, which disrupts the CASTOR1–GATOR2 complex, the three analogues belong to the non-disruption group and are thus potential drug candidates for mTORC1 inhibition.

**Discussion**

mTORC1 hyperactivation causes many complex diseases such as cancer, neurological disorders, metabolic diseases, and autoimmune diseases. Therefore, mTORC1 inhibition is a potentially effective therapeutic strategy. mTORC1 inhibition can be realized by maintaining integrity of the CASTOR1–GATOR2 complex in vivo. Because arginine

---

**Figure 5.** Frequency of hydrogen bond formation between arginine analogues and surrounding amino acid residues of cytosolic arginine sensor for mechanistic target of rapamycin complex 1 subunit 1. Each row corresponds to a specific hydrogen bond. The columns correspond to time zones dividing the 100 ns simulation time. The colours indicate the times of H-bond formation: the darker the colour, the more frequent the H-bond formation.
Figure 6. Continued
can bind with CASTOR1 and disrupt the CASTOR1–GATOR2 complex, it is crucial to prevent arginine from binding with CASTOR1. An attractive idea is to find arginine analogues that are as competent as arginine in binding with CASTOR1 but do not disrupt the CASTOR1–GATOR2 interaction.

In this study, we performed MD simulation of the interaction of arginine analogues with the protein CASTOR1. The RMSD and RMSF analyses revealed key features of the atomic level dynamics, which agree with the structural features of the protein–ligand interaction, thus demonstrating the validity of our approach. The analyses also highlighted the differences in binding dynamics among arginine analogues. The binding free energy calculations revealed that \( N_\alpha \)-acetyl-arginine, citrulline, and norarginine have sufficient binding affinity with CASTOR1 to compete with arginine. The H-bond analysis revealed that norarginine, \( N_\alpha \)-acetyl-arginine and L-arginine have proficient H-bonds that can facilitate their entering the narrow binding pocket of CASTOR1. We therefore suggest that norarginine and \( N_\alpha \)-acetyl-arginine are the top drug candidates for testing experimentally and clinically. Moreover, \( N_\alpha \)-acetyl-arginine is the best choice because its binding affinity with CASTOR1 is very high, only lower than arginine and arginine-OMe. Importantly, \( N_\alpha \)-acetyl-arginine forms more hydrogen bonds with CASTOR1 than arginine, which should confer additional advantages in binding with CASTOR1.

**Conflicts of Interest**

The Authors declare no conflicts of interest in regard to this study.
Authors’ Contributions

GW, WS, GRFK designed research; LS and XL performed research; LS, XL, JP, JM, YY, DW, WS, GRFK, GW analysed data; LS, XL, DW, and GW wrote the article. All Authors read and approved the final article.

Acknowledgements

This work was partly supported by National Natural Science Foundation of China (61773196), Guangdong and Shenzhen Research Funds (JCYJ20170307104535885 and JCYJ20170817104740861, ZDSYS20140509142721429, 2017B030301018, 2019B030301001), Shenzhen Peacock Plan (KQTD2016053117035204), and by Center for Computational Science and Engineering of Southern University of Science and Technology.

References

1 Ayuk SM and Abrahamse H: mTOR signaling pathway in cancer targets photodynamic therapy in vitro. Cells 8(5): 431, 2019. PMID: 31075885. DOI: 10.3390/cells8050431
2 Catania C, Binder E and Cota D: MTOR1 signaling in energy balance and metabolic disease. Int J Obs 35(6): 751-761, 2011. PMID: 20877289. DOI: 10.1038/ijo.2010.208
3 Suzuki R, Lee K, Jing E, Biddinger SB, McDonald JG, Montine TJ, Craft S and Kahn CR: Diabetes and insulin in regulation of brain cholesterol metabolism. Cell Metab 12(6): 567-579, 2010. PMID: 21109190. DOI: 10.1016/j.cmet.2010.11.006
4 Kitada M, Ogru Y, Suzuki T, Sen S, Lee SM, Kanasaki K, Kume S and Koya D: A very-low-protein diet ameliorates advanced diabetic nephropathy through autophagy induction by suppression of the mTORC1 pathway in Wistar fatty rats, an animal model of type 2 diabetes and obesity. Diabetologia 59(6): 1307-1317, 2016. PMID: 27020449. DOI: 10.1007/s00125-016-3925-4
5 Roberto Z, Alejo E and Sabatini DM: mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12(4): 21-35, 2011. PMID: 21157483. DOI: 10.1038/nrm3025
6 Hallett JEH and Manning BD: Castoring new light on amino acid sensing. Cell 165(1): 15-17, 2016. PMID: 27015302. DOI: 10.1016/j.cell.2016.03.002
7 Wang G and Krueger GRF: Computational analysis of mTOR signaling pathway: Bifurcation, carcinogenesis, and drug discovery. Anticancer Res 30(7): 2683-2688, 2010. PMID: 20682998. DOI: 10.1097/CAD.0b013e32833ab7a0
8 Xiaojun Max M and John B: Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10(5): 307-318, 2009. PMID: 19339977. DOI: 10.1038/nrm2672
9 Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell 124(3): 471-484, 2006. PMID: 16469695. DOI: 10.1016/j.cell.2006.01.016
10 Xia J, Wang R, Zhang T and Ding J: Structural insight into the arginine-binding specificity of CASTOR1 in amino acid-dependent mTORC1 signaling. Cell Discov 2: 16035, 2016. PMID: 27648300. DOI: 10.1038/celldisc.2016.35
11 Chantranupong L, Scaria S, Saxton R, Gygi M, Shen K, Wyant G, Wang T, Harper JW, Gygi S and Sabatini D: The castor proteins are arginine sensors for the mTORC1 pathway. Cell 165(1): 153-164, 2016. PMID: 26972053. DOI: 10.1016/j.cell.2016.02.035
12 Sancak Y, Peterson TR, Shaul YD, Linquist RA, Thoreen CC, Bar-Peled L and Sabatini DM: The RAG GTPases bind RAPTOR and mediate amino acid signaling to mTORC1. Science 320(5882): 1496-1501, 2008. PMID: 18497260. DOI: 10.1126/science.1157535
13 Bar-Peled L, Schweitzer LD, Zoncu R and Sabatini DM: RAGULATOR is a GEF for the RAG GTPases that signal amino acid levels to mTORC1. Cell 150(6): 1196-1208, 2012. PMID: 22980980. DOI: 10.1016/j.cell.2012.07.032
14 Tsun ZY, Bar-Peled L, Chantranupong L, Zoncu R, Wang T, Kim C, Spooner E and Sabatini DM: The folliculin tumor suppressor is a GAP for the RAGC/D GTPases that signal amino acid levels to mTORC1. Mol Cell 52(4): 495-505, 2013. PMID: 24095279. DOI: 10.1016/j.molcel.2013.09.016
15 Bar-Peled L and Sabatini DM: Regulation of mTORC1 by amino acids. Trends Cell Biol 24(7): 400-406, 2014. PMID: 24698685. DOI: 10.1016/j.tcb.2014.03.003
16 Kim E, Goraksha-Hicks P, Li L, Neufeld TP and Guan KL: Regulation of TORC1 by RAG GTPases in nutrient response. Nat Cell Biol 10(8): 935-945, 2008. PMID: 18604198. DOI: 10.1038/ncc1753
17 Bar-Peled L, Chantranupong L, Cherniack AD, Chen WW, Ottina KA, Grabner BC, Spear ED, Carter SL, Meyerson M and Sabatini DM: A tumor suppressor complex with GAP activity for the RAG GTPases that signal amino acid sufficiency to mTORC1. Science 340(6136): 1100-1106, 2013. PMID: 23723238. DOI: 10.1126/science.1230444
18 Saxton RA, Chantranupong L, Knochenhauer KE, Schwartz TU and Sabatini DM: Mechanism of arginine sensing by CASTOR1 upstream of mTORC1. Nature 536(7615): 229-233, 2016. PMID: 27487210. DOI: 10.1038/nature19079
19 Wolison RL, Chantranupong L, Saxton RA, Shen K, Scaria SM, Cantor JR and Sabatini DM: Sestrin2 is a leucine sensor for the mTORC1 pathway. Science 351(6268): 43-48, 2016. PMID: 26449471. DOI: 10.1126/science.aab2674
20 Saxton RA, Chantranupong L, Knochenhauer KE, Schwartz TU and Sabatini DM: Mechanism of arginine sensing by CASTOR1 upstream of mTORC1. Nature 536(7615): 229-233, 2016. PMID: 27487210. DOI: 10.1038/nature19079
21 Panchenko AR, Wang J, Nienhaus GU and Wolynes PG: Analysis of ligand binding to heme proteins using a fluctuating path description. J Phys Chem 99(22): 9278-9282, 1995. PMID: 27487210. DOI: 10.1038/nature19079
22 Liyong G, Zhiqiang Y, Xiliang Z, Liang H, Yongliang Y and Jin W: A comparison of various optimization algorithms of protein-ligand docking programs by fitness accuracy. J Mol Model 20(7): 2251, 2014. PMID: 24935106. DOI: 10.1007/s00894-014-2251-3
23 Trott O and Olson AJ: Autodock vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2): 455-461, 2010. PMID: 19499576. DOI: 10.1002/jcc.21334
24 Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW and Klein ML: Comparison of simple potential functions for simulating liquid water. J Chem Phys 79(2): 926-935, 1983. DOI: 10.1063/1.445869
25 Salomon-Ferrer R, Case DA and Walker RC: An overview of the AMBER biomolecular simulation package. WIREs Comput Mol Sci 3(2): 198-210, 2013. DOI: 10.1002/wcms.1121
